ADC Therapeutics SA (ADCT) Stock Analysis
Verdict: AVOID
ZYNLONTA sales offer top-line support with a ~22-month cash runway, but $439M total debt and negative equity make dilution risk severe.
Investment score: 39/100
Analysis as of
Is ADC Therapeutics SA stock worth reviewing? AI model thesis
The AI model considers ADCT an AVOID for standard growth portfolios due to negative equity of -185.83M USD and 439.01M USD in total debt. Despite ZYNLONTA revenue and a 261.34M USD cash cushion (~22 months of runway), heavy leverage and recent analyst downgrades create high risk of equity dilution.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
ADC Therapeutics SA opportunities and risks
What speaks for ADCT
- ZYNLONTA commercial traction supports 2025 revenue of 81.36M USD with high 88.7% TTM gross margins.
What speaks against ADCT
- Total debt overhang of 439.01M USD poses acute solvency and equity dilution risk by 2027.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ADCT | n/a | 2.1x | n/a | 88.7% | -123.0% | -60.9% |
| MLTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.6% |
| ACIU | n/a | 13.8x | n/a | 100.0% | -246.5% | -14.5% |
| Peer median | n/a | 6.9x | n/a | 50.0% | -123.2% | -16.1% |
Frequently asked questions about ADC Therapeutics SA (ADCT)
Is ADCT stock a good investment?
The cached TradeMates AI model rates ADC Therapeutics SA as AVOID with an investment score of 39/100. The AI model considers ADCT an AVOID for standard growth portfolios due to negative equity of -185.83M USD and 439.01M USD in total debt. Despite ZYNLONTA revenue and a 261.34M USD cash cushion (~22 months of runway), heavy leverage and recent analyst downgrades create high risk of equity dilution. This is algorithmic model output, not personal investment advice.
Is ADCT stock a buy?
The TradeMates model verdict for ADCT is AVOID with an investment score of 39/100. Treat this as a model signal to review, not a personal buy recommendation.